Tue, Aug. 12, 8:54 AM
Tue, Aug. 12, 7:09 AM
Tue, Aug. 5, 7:41 AM
- The USPTO issues patent No. 8,796,204 entitled "Beta-Arrestin Effectors and Compositions and Methods of Use Thereof" to Trevena (NASDAQ:TRVN). The patent covers the method of use for TRV027, the company's product candidate for the treatment of acute heart failure. The patent will be in effect until at least 2029.
Fri, May. 9, 7:57 AM
Fri, Jan. 31, 10:04 AM
- The hot offering of the day following yesterday's near-triple in Dicerna Pharmaceuticals (DRNA) is Ultragenyx Pharmaceutical (RARE), which raised $121M after pricing its IPO at $21 each vs. an expected range of $14-$17. The company also upsized the offering amount by 1M shares to 5.8M.
- Cara Therapeutics (CARA) raised $55M after selling 5M shares at the low end of the expected $11-$13 range.
- Trevena (TRVN) - which two months ago postponed its offering due to market conditions - raised $64.75M after pricing its IPO at $7 per share.
TRVN vs. ETF Alternatives
Other News & PR